Acronym:
CS1002-101
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | All cancers | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase I | Tumour Stream | Solid Tumours |
Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Solid Tumours |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
A phase I, open-label, multiple dose, dose escalation study of the anti- CTLA-4 monoclonal antibody CS1002 in subjects with advanced solid tumors.
Lay Summary
Sponsor / Cooperative group
Cstone
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Ashford Cancer Centre Research | Helen Daykin | hdaykin@adelaidecancercentre.com.au | 08 8292 2240 | Recruiting |